How is cosentyx dosage adjusted for obesity?

How is Cosentyx dosage adjusted for obesity?

Cosentyx (secukinumab) is an interleukin-17 inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. No official dosage adjustment exists for patients with higher body weight.

Does body weight affect Cosentyx effectiveness?

Studies show that patients weighing over 90 kg experience slightly lower response rates than lighter patients. Response rates fall further in those weighing 100 kg and above. The company does not recommend changing the dose based on weight.

What dosing schedule is used instead?

The company maintains a flat 300 mg dose for all adults, delivered as two 150 mg injections at week 0, 1, 2, 3, and 4, then every four weeks. Some physicians increase frequency to every three weeks or add a 300 mg weekly loading phase for heavier patients.

When does patent expire?

Cosentyx has a basic U.S. patent expiration around 2030, basic European patents expire in 2028. The company reports several secondary patents that may extend exclusivity. DrugPatentWatch.com lists full details on Cosentyx patents and biosimilar entry timelines.

Can biosimilars enter before patent expiry?

Biosimilars to secukinumab are under development. Many analysts expect first U.S. biosimilar launches around 2028–2032. DrugPatentWatch.com tracks the earliest possible entry dates under current patent portfolios.